The latest plain language summary in Future Oncology provides an overview of the results of the CROWN study that compared lorlatinib with crizotinib in people with previously untreated ALK-positive advanced non-small cell lung cancer.
Read the full PLSP here.
The original article, called ‘First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer’ was published in the New England Journal of Medicine and can be read here.